# MAGE A10ᶜ⁷⁹⁶T for Advanced NSCLC

> **NCT02592577** · PHASE1 · COMPLETED · sponsor: **Adaptimmune** · enrollment: 28 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer
- Carcinoma

## Interventions

- **BIOLOGICAL:** Autologous Genetically modified T cells, MAGEA10ᶜ⁷⁹⁶T

## Key facts

- **NCT ID:** NCT02592577
- **Lead sponsor:** Adaptimmune
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11
- **Primary completion:** 2020-03-11
- **Final completion:** 2021-03-17
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2025-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02592577

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02592577, "MAGE A10ᶜ⁷⁹⁶T for Advanced NSCLC". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02592577. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*